Biotechnology Innovation Scorecard
IP Protection

Biotechnology Innovation Score Summary

The top-ranked countries in IP Protection are Finland, Canada, France, Ireland, Japan, the Netherlands, Qatar, the United Kingdom, and the United States.

Strong intellectual property (IP) protection is central to biotechnology. In fact, it is said that the scope of IP protection defines the scope of biotechnology innovation.

IP protection is so important in biotechnology because of the years of research, and substantial financial investments are required to produce novel biotechnology products. Without protection from competition or from reverse-engineering, innovators and their financiers would have no certainty of recouping their investments.

In the absence strong intellectual property protection, it is difficult to attract the necessary funding or to convince talented scientists and business founders to take on the risks of innovative research and development.

But IP protection also goes beyond encouraging domestic development. It can also be an important factor in encouraging foreign companies to develop products for domestic needs. For example, a company may elect not to pursue a drug lead if it can only be sold in countries where development costs are unlikely to ever be recovered.

The chart below shows the country scores for IP Protection, ordered by rank and alphabetically by country name. Scroll down to the IP Protection metrics for highlights of top performers in each metric.

IP Protection

Metric Highlights

Scores in these individual metrics are averaged to produce the overall category score shown above


Patent strength

The top-ranked countries in Patent strength are the United States, Belgium, Canada, Denmark, Finland, France, Ireland, Italy, Japan, and the Netherlands.

Perceived IP protection

The top-ranked countries in Perceived IP protection are Finland, Luxembourg, Singapore, and Switzerland.

Copyright © 2018 thinkBiotech LLC. Source data from Scientific American Worldview